ETERNA THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.79 USD | +3.12% |
|
-16.75% | -0.28% |
| Mar. 15 | North American Morning Briefing : Inflation -2- | DJ |
| Mar. 14 | Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 217 | 16.51 | 9.712 |
| Enterprise Value (EV) 1 | 202.8 | 6.245 | 43.98 |
| P/E ratio | -1.48 x | -0.4 x | -0.44 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | 142,816,824 x |
| EV / Revenue | - | - | 646,758,000 x |
| EV / EBITDA | -7.42 x | -0.23 x | -2.14 x |
| EV / FCF | -16,347,216 x | -609,485 x | -3,270,432 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 33.4 x | 1.36 x | 4.35 x |
| Nbr of stocks (in thousands) | 2,602 | 5,127 | 5,410 |
| Reference price 2 | 83.40 | 3.220 | 1.795 |
| Announcement Date | 4/15/22 | 3/20/23 | 3/14/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | 0.068 |
| EBITDA 1 | -16.29 | -8.857 | -7.15 | -27.31 | -27.07 | -20.59 |
| EBIT 1 | -16.43 | -8.878 | -7.248 | -27.43 | -27.23 | -20.68 |
| Operating Margin | - | - | - | - | - | -30,404.41% |
| Earnings before Tax (EBT) 1 | -18.1 | -8.937 | -26.53 | -122.3 | -24.53 | -21.67 |
| Net income 1 | -18.1 | -8.937 | -26.53 | -122.3 | -24.58 | -21.67 |
| Net margin | - | - | - | - | - | -31,864.71% |
| EPS | - | - | -30.17 | -56.49 | -8.061 | -4.081 |
| Free Cash Flow | - | -6.357 | -6.018 | -12.4 | -10.25 | -13.45 |
| FCF margin | - | - | - | - | - | -19,775.92% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/2/20 | 10/2/20 | 4/15/22 | 4/15/22 | 3/20/23 | 3/14/24 |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -86.33 | -9.105 | -6.296 | -13.88 | -8.304 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -86.06 | -8.458 | -9.375 | -3.406 | -7.311 |
| Net income 1 | -86.06 | -8.479 | -9.375 | -3.406 | -7.316 |
| Net margin | - | - | - | - | - |
| EPS 2 | -34.00 | - | -3.400 | -1.200 | -2.490 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/12/21 | 4/15/22 | 7/1/22 | 8/11/22 | 11/14/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 1.27 | - | - | 34.3 |
| Net Cash position 1 | 5.92 | 4.5 | - | 14.3 | 10.3 | - |
| Leverage (Debt/EBITDA) | - | - | -0.1773 x | - | - | -1.664 x |
| Free Cash Flow | - | -6.36 | -6.02 | -12.4 | -10.2 | -13.4 |
| ROE (net income / shareholders' equity) | - | -88.9% | 2,887% | 4,816% | -131% | -302% |
| ROA (Net income/ Total Assets) | - | -35% | -31.4% | -74.2% | -63.3% | -36.2% |
| Assets 1 | - | 25.56 | 84.58 | 164.8 | 38.86 | 59.87 |
| Book Value Per Share | - | - | -13.10 | 2.500 | 2.360 | 0.4100 |
| Cash Flow per Share | - | - | 1.850 | 6.530 | 2.230 | 1.400 |
| Capex 1 | 0.08 | 0.61 | 0.04 | 0.15 | 0.3 | 0.02 |
| Capex / Sales | - | - | - | - | - | 27.94% |
| Announcement Date | 10/2/20 | 10/2/20 | 4/15/22 | 4/15/22 | 3/20/23 | 3/14/24 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -0.28% | 9.68M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ERNA Stock
- Financials Eterna Therapeutics Inc.
